Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •1. Inability to take oral medications or gastrointestinal abnormalities potentially impacting absorption.
• •2. Current enrollment or past participation in another clinical trial.
• •3. Unresolved adverse reactions (except alopecia) from previous cancer-directed therapy.
• •4. Use of cancer-directed therapies, including chimeric antigen receptor T cell therapy.
• •5. Autologous transplantation within 60 days.
• •6. Prior allogeneic transplantation.
• •7. Major surgery within 30 days, or unresolved complications after a major or minor surgery.
• •8. History of or currently active cardiovascular disease.
• •9. Clinically significant respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders.
• •10. History of other malignancy.